USPTO issues patent to Aeris’ cross-linked polymers for treatment of emphysema

Aeris Therapeutics, LLC announced that the U.S. Patent and Trademark Office has issued a patent covering the use of cross-linked polymers administered into the lung to reduce lung volume for the treatment of emphysema. This newly issued patent, entitled "Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers," covers novel technology that enables lung volume reduction therapy without high risk surgery.    

"The issuance of this patent is an important step forward in strengthening the intellectual property covering the AeriSeal® System and Aeris' position as the leader in endoscopic lung volume reduction," commented David Dove, MD, CEO of Aeris. "Designing and protecting innovative methods of treating emphysema is critical to our mission of advancing new therapies that improve the lives of patients with advanced lung disease into clinical use."

Source: Aeris Therapeutics